Vident Advisory LLC Makes New Investment in ICU Medical, Inc. $ICUI

Key Points

• Vident Advisory LLC made a significant investment in ICU Medical, Inc., acquiring 1,942 shares valued at approximately $270,000 in the first quarter of 2023.
• ICU Medical's recent quarterly earnings report exceeded analysts' expectations, with earnings per share of $2.10, beating the consensus estimate of $1.44.
• Analysts have generally upgraded their ratings on ICU Medical, with a consensus rating of "Buy" and an average price target of $179.00.

Vident Advisory LLC bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,942 shares of the medical instruments supplier's stock, valued at approximately $270,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 153 shares during the last quarter. Blue Trust Inc. increased its stake in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after acquiring an additional 150 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in ICU Medical during the first quarter worth $235,000. Xponance Inc. increased its stake in ICU Medical by 5.3% during the first quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after acquiring an additional 86 shares during the last quarter. Finally, Tidal Investments LLC acquired a new stake in ICU Medical during the fourth quarter worth $342,000. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Price Performance

Shares of ICUI opened at $130.57 on Wednesday. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26. The firm's fifty day simple moving average is $126.39 and its 200-day simple moving average is $134.20. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -85.90 and a beta of 0.86. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same period last year, the business earned $1.56 EPS. The company's revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David C. Greenberg acquired 1,200 shares of ICU Medical stock in a transaction dated Wednesday, August 27th. The shares were acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the acquisition, the director owned 7,960 shares of the company's stock, valued at $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Vivek Jain purchased 21,929 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the purchase, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Raymond James Financial dropped their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. Finally, Piper Sandler began coverage on ICU Medical in a research report on Friday, August 15th. They issued an "overweight" rating and a $145.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $179.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.